Latest News for: dsmb

Edit

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

The Galveston Daily News 04 Dec 2025
EMERYVILLE, Calif.--(BUSINESS WIRE)--Dec 4, 2025-- ....
Edit

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation (Form 8-K) (Estrella Immunopharma Inc)

Public Technologies 04 Dec 2025
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation ● An ... ● DSMB recommends advancement of STARLIGHT-1 to Phase II at the Recommended Phase II Dose (RP2D).
Edit

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB

Hastings Tribune 01 Dec 2025
Vancouver, Canada, Dec ... (Nasdaq. CMND), (FSE.
Edit

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New ...

Nasdaq Globe Newswire 01 Dec 2025
Vancouver, Canada, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq. CMND), (FSE ... .
Edit

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in ...

Nasdaq Globe Newswire 22 Oct 2025
BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to ...
Edit

DSMB warning after \u2018avoidable\u2019 Scapa diver prop death

Divernet 17 Oct 2025
Lack of dive-boat look-outs ...
Edit

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial ...

Business Wire 07 Oct 2025
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT ... .
Edit

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT (Maat Pharma SA)

Public Technologies 07 Oct 2025
The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The DSMB recommended that the study continue as planned.
Edit

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

Pharmiweb 07 Oct 2025
The DSMB conducted an unblinded safety review of data from the first 120 enrolled patients and identified no safety concerns and no excessive mortality related to MaaT033 as of today. The DSMB recommended that the study continue as planned.
Edit

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury

Nasdaq Globe Newswire 24 Sep 2025
Independent DSMB reports zero device-related safety issues. Supports potential clinical benefit. Trial sample size re-estimated to strengthen statistical power ... .
Edit

SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in

Hastings Tribune 24 Sep 2025
Independent DSMB reportszero device-related safety issues ... .
Edit

SeaStar Medical Reports DSMB Recommendation to Continue theNEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury (Form 8-K) (Seastar Medical Holding Corporation)

Public Technologies 24 Sep 2025
SeaStar Medical Reports DSMB Recommendation to Continue the ... Independent DSMB reports zero device-related safety issues ... The interim analysis by the independent DSMB evaluated the ... The DSMB reported.
  • 1

Article Search

tools
×
×
×
×